AMD

Treatment for geographic atrophy lacks efficacy in Phase 2 studyIn a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.
TREX-AMD trial finds visual gains from treat-and-extend vs. monthlyTreat-and-extend approach for neovascular AMD leads to beneficial results in 2-year clinical trial.
Transplantable 3-D retinasAIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.
Seeing the reality of artificial vision
Seeing the reality of artificial visionOphthalmology may be one step closer to the hope of providing artificial vision for individuals affected by virtually all forms of blindness.
Treat-and-extend may lead to better AMD resultsTreating neovascular age-related macular degeneration (nAMD) patients with anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis, Genentech) on a monthly regimen has produced “great results” in clinical trials, said Prof. Mark C. Gillies, MBBS, PhD. “But what happens after that and what happens in real world practice?”
‘Ideal’ disease control leads to better nAMD outcomesNeovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Researchers reject vitamin D role in macular degeneration
Researchers reject vitamin D role in macular degenerationAnalyzing data from the European Eye Study, Gareth J. McKay, PhD, of Queen’s University in Belfast, United Kingdom, and colleagues in 7 countries in Europe found no meaningful association between serum 25-hydroxy vitamin D (25(OH)D) and AMD. They published the finding in Ophthalmology.
Visual cycle metabolites: Cause of AMD?
Visual cycle metabolites: Cause of AMD?Oxidative stress stemming from a growing accumulation of visual cycle adducts may play an important role in the pathogenesis of AMD, suggest new findings.
Dry AMD therapy evolves with photobiomodulationNon-invasive photobiomodulation may help dry age-related macular degeneration by causing regression of drusen and improving retinal function with benefits in visual acuity and contrast sensitivity.